重组水蛭素克隆的表达及其产物的分离纯化

来源 :中华血液学杂志 | 被引量 : 0次 | 上传用户:lkekej1314
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
目的:在原核细胞中表达具有生物活性的重组水蛭素变异物1(rHV1)并进行重组产物的分离纯化研究。方法:以质粒pBV220为载体,在大肠杆菌DH5α中表达rHV1,发色底物法测定其抗凝血酶生物活性;利用超滤、DEAE-SephadexA-50以及凝血酶亲合层析进行重组产物的分离纯化。结果:在大肠杆菌中获得了rHV1的活性表达,表达量约占总蛋白的16.9%,活力达到20~30ATU/ml培养液;初步的纯化研究得到了具抗凝生物活性的rHV1纯品,SDS聚丙烯酰胺凝胶电泳呈单一条带。结论:重组水蛭素变异物1的活性表达及其分离纯化研究填补了国内空白,为研制国产高效重组抗凝药物带来希望。 Objective: To express bioactive hirudin mutant 1 (rHV1) in prokaryotic cells and to study the isolation and purification of recombinant hirudin. Methods: The plasmid pBV220 was used as a vector to express rHV1 in E. coli DH5α, and its antithrombin biological activity was assayed by chromogenic substrate method. The recombinant protein was characterized by ultrafiltration, DEAE-Sephadex A-50 and thrombin affinity chromatography Isolation and Purification. Results: The expression of rHV1 in Escherichia coli was about 16.9% of the total protein and its activity was 20 ~ 30ATU / ml. The purified rHV1 with anticoagulant activity SDS polyacrylamide gel electrophoresis showed a single band. CONCLUSION: The study on the activity of recombinant hirudin mutant 1 and its isolation and purification have filled the gap in our country and brought hope for the development of highly efficient recombinant anticoagulant drugs in China.
其他文献